LGND — LIGAND PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying LGND?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their LGND position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Contraction regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.
- +3 tracked investors reported holding LGND at their latest filing
- +Macro Health is 55/100 in a Contraction regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/17/2026.
About LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $6M. Across recent filings, tracked investors recorded 3 new positions, 1 increased, 1 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in LGND
How many top investors track LGND
A small number of top investors own this.
LGND Ownership Composition
How LIGAND PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting LGND
1 tracked investor has since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares11.7KValue$3.7M% Portfolio0.00%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares800Value$252.9K% Portfolio0.00%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares4KValue$1.3M% Portfolio0.00%
Previously held LGND
These investors reported LGND in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Ray Dalio | Bridgewater Associates | 4.2K | $795 | Dec 31, 2025 |
Recent activity
- New$3.6KNov 14, 2025
- Reduced$2.5K(-35.53%)Feb 17, 2026
- New$228Nov 13, 2025
- Increased$795(226.63%)Feb 13, 2026
- Sold$0(-100.00%)May 15, 2026
- New$3MNov 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
Frequently asked questions
- How many institutional investors hold LGND?
- 3 tracked institutional investors disclosed a position in LGND (LIGAND PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of LGND?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in LGND, valued at $6M.
- Did institutional ownership of LGND increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 1 increased, 1 reduced, and 2 fully exited LGND.
- Where does this LGND ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.